Fundraising Fox

Aqemia

Founded 2019 · 84 employees on LinkedIn · 6 known investors

Find your way into Aqemia

171 people in our graph share verified history with the Aqemia team — schools, employers, funds. One of them is your warm intro.

Pierre Galletunlockedknows Maximilien Levesque · together at CEA (overlapped)
knows the team · via University of Oxford
×2knows the team · via CEA
×2knows the team · via Ecole normale supérieure
×3knows the team · via CNRS
×3knows the team · via EDF

Aqemia applies atomic-scale physics and generative AI to accelerate drug discovery and molecular design, enabling faster identification of innovative medicines for unmet therapeutic needs. The company uses proprietary deep physics algorithms and machine learning to predict drug properties and design novel molecules, serving pharmaceutical and biotech organizations.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Aqemia was founded in 2019 by Maximilien Levesque and Emmanuelle Martiano-Rolland.

MLMaximilien Levesque
Maximilien LevesqueinPhD, Prof., CEO and Co-FounderMaximilien Levesque holds a PhD in quantum mechanics and spent over a decade in drug discovery research, including six years as a research group leader at École normale supérieure Paris developing computational methods for molecular design. He is CEO and Co-Founder of Aqemia, which applies physics-based AI to accelerate pharmaceutical research and drug discovery.
EM
Emmanuelle Martiano-RollandinCOO and Co-Founder

Investors · 6

Cathay InnovationParis · $5M – $40Mvia Jacky Abitbol · led
ElaiaParis · $108K – $1.6M
PSL Innovation FundParis
Bpifrancereported · 2 sourcesParis, Ile-De-France · $270K
Eurazeoreported · 2 sourcesParis

Also in the syndicate · 1

Wendel Growth

Funding

SEC filings, press & company announcements

$38M disclosed across 1 of 3 rounds · 2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Aqemia raises $38M to find new drugs by meshing theoretical physics with GenAI | TechCrunchtechcrunch.com · Dec 2024Aqemia Raises $38M in Fundingfinsmes.com · Dec 2024Aqemia Raises €60m in Series A Funding to Advance AI-Driven Drug Discoverybiopharmatrend.com · Feb 2024Aqemia Raises Additional €30M in Series Afinsmes.com · Jan 2024

Frequently asked questions

What does Aqemia do?
Aqemia applies atomic-scale physics and generative AI to accelerate drug discovery and molecular design, enabling faster identification of innovative medicines for unmet therapeutic needs. The company uses proprietary deep physics algorithms and machine learning to predict drug properties and design novel molecules, serving pharmaceutical and biotech organizations.
Who founded Aqemia?
Aqemia was founded by Maximilien Levesque, Emmanuelle Martiano-Rolland in 2019.
Who are Aqemia's investors?
Aqemia's investors include Cathay Innovation, Elaia, PSL Innovation Fund, Bpifrance, Eurazeo.
How much funding has Aqemia raised?
Aqemia has disclosed $38M raised across 1 of its 3 known rounds.